Tag: AHA 2022
Rates of all-cause death align between invasive and conservative strategies in ISCHEMIA-EXTEND
Extended follow-up of the ISCHEMIA-EXTEND trial has shown no difference in rates of all-cause mo...
BRIGHT-4 trial: Bivalirudin cuts 30-day mortality for STEMI patients undergoing PCI compared to heparin
Bivalirudin is a safer and more effective anticoagulant than heparin for treating patients with ST-s...
AHA 2022: SPYRAL HTN-ON MED study demonstrates “meaningful clinical benefits” consistent with other renal denervation trials
Medtronic has announced the six-month results from the full cohort of the SPYRAL HTN-ON MED clin...
AHA 2022: First data from BEST-CLI bring surgical bypass into the forefront of discussion for patients with high-quality great saphenous vein
The first results from the BEST-CLI randomised controlled trial (RCT) of 1,830 patients show tha...
